Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid

Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary...

Descripción completa

Detalles Bibliográficos
Autores principales: Seyed Jafari, S. Morteza, Feldmeyer, Laurence, Bossart, Simon, Simon, Dagmar, Schlapbach, Christoph, Borradori, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879677/
https://www.ncbi.nlm.nih.gov/pubmed/33584689
http://dx.doi.org/10.3389/fimmu.2020.611549
Descripción
Sumario:Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series. More recently, dupilumab, an interleukin (IL)-4-receptor alpha antagonist, also showed promising preliminary results. We describe a patient with refractory BP who showed a complete response to a combination therapy with omalizumab and dupilumab.

Ejemplares similares